EDITORIAL BOARD MEMBERS
Department of Pharmacology and Experimental Neuroscience
Department of Pharmaceutical Sciences, Univeristy of Nebraska Medical Center
Dr. Xinming Liu is an Assistant Professor in the Department of Pharmacology and Experimental Neuroscience, College of Medicine, and a courtesy faculty in the Department of Pharmaceutical Sciences, College of Pharmacy, at the University of Nebraska Medical Center (UNMC). Dr. Liu’s research mainly focuses on the development and evaluation of drug delivery systems, nanomedicine and small molecule prodrugs for treatment of human diseases. His research is highly technology- and science-driven, with strong translational emphasis on targeted therapy of HIV/AIDS, inflammatory diseases and orofacial diseases. Dr. Liu’s research results in 15 US and worldwide patents (e.g. WO, US, AU, CA, CN, EP, JP, KR), 3 licensed technologies and 2 start-up pharmaceutical companies. In addition to his multiple technological accomplishments, Dr. Liu excels in scholarship as documented by 39 peer-reviewed publications in leading drug delivery journals, including Biomaterials, Nanomedicine, and Journal of Controlled Release. Dr. Liu presented his research at various professional meetings (AAPS, CRS, IADR, NanoDDS, ASBMR, SNIP) as an active member. Dr. Liu is also very active in academic services, and is serving for more than 10 leading peer-reviewed scientific journals as a regular reviewer or editorial board member. In recognition of Dr. Liu’s achievements, he was awarded the 2007 American Society for Bone and Mineral Research Young Investigator Award, 2007 CRS Innovative Aspects of Oral Drug Delivery & Absorption Award, 2009 UNMC Postdoctoral Scholar Award, 2010 UNeMed Research Innovation Award, and 2012 Nebraska N. Badami Distinguished Scientist Award.
Dr. Liu’s research interests mainly focus on chemically engineering novel biomaterials, drug delivery systems (DDS), nanomedicine, and low-molecular-weight prodrugs for the targeting theranostic application of HIV, CNS diseases, cancer, inflammatory diseases, and orofacial diseases. Specific areas include:
• Nanoformulated antiretroviral therapeutics (NanoART) for the targeted and long-acting therapy of HIV/AIDS.
• Liposomes, micelles and solid lipid nanoparticles (SLN) for CNS, inflammatory, and orofacial diseases.
• Ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles for the targeting theranostic application of Cancer and CNS diseases.
• Polymer therapeutics for CNS diseases, cancer, inflammatory diseases and orofacial diseases.
• Novel targeting Prodrug design.